2023-505455-44-00已完成2 期
A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301)
Amgen Inc.56 个研究点 分布在 14 个国家目标入组 300 人开始时间: 2022年3月28日最近更新:
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 300
- 试验地点
- 56
- 主要终点
- Phase 1b: Dose-limiting toxicities (DLTs), treatment-emergent adverse events, treatment-related adverse events, and clinically significant changes in vital signs, visual acuity, and clinical laboratory tests
研究概览
简要总结
Phase 1b: To observe the safety and tolerability of bemarituzumab Phase 2: To evaluate preliminary antitumor activity
研究设计
- 分配方式
- Na
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed cancer of one of the following types, refractory to or relapsed after at least 1 prior standard therapeutic regimen in the advanced/metastatic setting, as specified below. If no standard of care therapies exists for the subject, or the subject cannot tolerate or refuses standard of care anticancer therapy, the subject may be allowed to participate on the study after discussion between the investigator and Amgen medical monitor. Subjects who have not received all approved or standard treatments for their cancer must be informed that these alternatives to receiving bemarituzumab are available prior to consenting to participate in the trial. head and neck squamous cell carcinoma: ≥ 1 line of therapy triple-negative breast cancer: ≥ 2 lines of therapy intrahepatic cholangiocarcinoma: ≥ 1 line of therapy Lung adenocarcinoma: at least platinum-based chemotherapy, checkpoint inhibitor, and targeted therapy (ie, if molecular testing has identified targetable mutations in EGFR, ALK, etc) platinum-resistant ovarian epithelial carcinoma, including fallopian tube cancers and primary peritoneal cancers, defined as progression during or within 6 months of a platinum containing regimen: ≥ 1 line of therapy endometrial adenocarcinoma: ≥ 1 line of therapy cervical carcinoma: ≥ 1 line of therapy other solid tumors: ≥ 1 line of therapy
- •Tumor overexpresses FGFR2b as determined by centrally performed IHC testing
- •Measurable disease per RECIST v1.1
- •Adequate hematologic and organ function, defined as follows: Absolute neutrophil count ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Hemoglobin ≥ 9 g/dL AST and ALT < 3 x upper limit of Normal [ULN] (or < 5 x ULN in case of liver involvement). Total bilirubin < 1.5 x ULN (or < 2 x ULN in case of liver involvement or Gilbert’s disease) Calculated or measured creatinine clearance (CrCl) of ≥ 30 mL/minute calculated using the formula of Cockcroft and Gault ([140 – Age] x Mass[kg]/[72 x Creatinine mg/dL) (x 0.85 if female). International normalized ratio (INR) or prothrombin time (PT) < 1.5 × ULN except for subjects receiving anticoagulation therapy, who must be on stable dose of anticoagulant therapy for 6 weeks prior to enrollment.
排除标准
- •Untreated or symptomatic central nervous system (CNS) metastases or leptomeningeal disease Subjects with asymptomatic CNS metastases are eligible if clinically stable for at least 4 weeks and do not require intervention (including use of corticosteroids). Subjects with treated brain metastases are eligible provided the following criteria are met: Definitive therapy was completed at least 2 weeks prior to the first planned dose of study treatment (stereotactic radiosurgery at least 7 days prior to first planned dose of study treatment). At least 7 days prior to first planned dose of study treatment: any CNS disease is clinically stable, subject is off steroids for CNS disease (unless steroids are indicated for a reason unrelated to CNS disease), and subject is off or on stable doses of anti-epileptic drugs.
- •Major surgical procedure within 28 days prior to first dose of study treatment
- •Female subjects of childbearing potential unwilling to use protocol specified method of contraception during treatment and for an additional 90 days after the last dose of bemarituzumab.
- •Other solid tumor cohort excludes primary tumors of the CNS, squamous non-small cell lung cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma
- •History of other malignancy within the past 2 years, with the following exceptions: curatively treated non-melanoma skin malignancy cervical cancer in situ curatively treated uterine cancer stage I curatively treated ductal or lobular breast carcinoma in situ and not currently receiving any systemic therapy localized prostate cancer that has been treated surgically with curative intent and presumed cured
- •Impaired cardiac function or clinically significant cardiac disease including: unstable angina within 6 months prior to first dose of study treatment, acute myocardial infarction < 6 months prior to first dose of study treatment, New York Heart Association (NYHA) class II-IV congestive heart failure, uncontrolled hypertension (defined as an average systolic blood pressure > 160 mmHg or diastolic >100 mmHg despite optimal treatment, uncontrolled cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin, active coronary artery disease or corrected QT interval (QTc) ≥
- •Active infection requiring systemic treatment or any uncontrolled infection within 14 days prior to first dose of study treatment
- •Known human immunodeficiency virus (HIV) infection with CD4+ T-cell (CD4+) counts <350 cells/μL, hepatitis C infection (subjects with hepatitis C that achieve a sustained virologic response following antiviral therapy are allowed), or hepatitis B infection (subjects with hepatitis B surface antigen [SAg] or core antibody that achieve sustained virologic response with antiviral therapy directed at hepatitis B are allowed).
- •History of systemic disease or ophthalmologic disorders requiring chronic use of ophthalmic steroids
- •Prior treatment with any investigational selective inhibitor of the FGF-FGFR pathway (unless approved standard of care for tumor indication)
- •Any anticancer therapy or immunotherapy within 4 weeks prior to enrollment; Palliative radiotherapy is allowed, provided it has been completed more than 14 days prior to the first dose of study treatment All treatment-related toxicity needs to be resolved to grade ≤ 1 prior to the first dose of study treatment, with exception of alopecia or toxicities considered irreversible (defined as having been present and stable > 21 days) which are not otherwise described in the exclusion criteria
研究组 & 干预措施
Bemarituzumab
Test
干预措施: Bemarituzumab (Drug)
结局指标
主要结局
Phase 1b: Dose-limiting toxicities (DLTs), treatment-emergent adverse events, treatment-related adverse events, and clinically significant changes in vital signs, visual acuity, and clinical laboratory tests
Phase 1b: Dose-limiting toxicities (DLTs), treatment-emergent adverse events, treatment-related adverse events, and clinically significant changes in vital signs, visual acuity, and clinical laboratory tests
Phase 2: Objective response (OR) (OR = complete response [CR] + partial response [PR]), measured by computed tomography (CT) or magnetic resonance imaging (MRI) as determined by investigator per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
Phase 2: Objective response (OR) (OR = complete response [CR] + partial response [PR]), measured by computed tomography (CT) or magnetic resonance imaging (MRI) as determined by investigator per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
次要结局
- Phase 1b and 2: Overall survival (OS)
- Phase 1b: Objective response (OR)
- Phase 1b and 2: Disease control (DC) (CR, PR, or stable disease [SD])
- Phase 1b and 2: Time to response (TTR)
- Phase 1b: PK parameters for bemarituzumab including, but not limited to, area under the concentration time curve (AUC), maximum observed serum concentration (Cmax), and the observed concentration at the end of a dose interval (Ctrough)
- Phase 2: PK parameters for bemarituzumab including, but not limited to, AUC, Cmax, and Ctrough
- Phase 2: Treatment-emergent adverse events, treatment-related adverse events, and clinically significant changes in vital signs, visual acuity, and clinical laboratory tests
- Phase 1b and 2: Duration of response (DOR)
- Phase 1b and 2: Progression-free survival (PFS)
研究者
Medical Information
Scientific
Amgen Inc.
研究点 (56)
Loading locations...
相似试验
招募中
2 期
Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Immune ThrombocytopeniaNCT07362199Institute of Hematology & Blood Diseases Hospital, China20
招募中
2 期
A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung CancerSmall Cell Lung Cancer (SCLC)SCLC, Extensive StageNCT07358676Tianjin Medical University Cancer Institute and Hospital25
招募中
2 期
Pembrolizumab + Lenvatinib for First Line Non-Clear Cell, Renal Cell Carcinoma2023-504944-32-00Merck Sharp & Dohme LLC59
招募中
2 期
Substudy 06C: Combination Therapies in Gastroesophageal Adenocarcinoma2023-509307-33-00Merck Sharp & Dohme LLC26
招募中
3 期
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic DermatitisAtopic Dermatitis2023-508235-31-00Almirall S.A.522